Viewing Study NCT06241742



Ignite Creation Date: 2024-05-06 @ 8:05 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06241742
Status: COMPLETED
Last Update Posted: 2024-02-20
First Post: 2024-01-15

Brief Title: Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
Sponsor: Halia Therapeutics Inc
Organization: Halia Therapeutics Inc

Study Overview

Official Title: A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction
Status: COMPLETED
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal

The main question it aims to answer are

Does HT-6184 decrease inflammation in patients after third molar removal
Does HT-6184 decrease pain in patients after third molar removal

Participants will be asked to do the following during the clinical trial

Take a single oral dose of HT-6184 or placebo
Allow a oral surgeon remove their third molar teeth
Blood draws on 5 occurrences
Rate their pain intensity
Attend two follow-up appointments on day 1 and day 2 after third molar removal
Participate in one follow-up phone call 5-7 days after third molar removal
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None